If your company is paying wildly different prices for the same infusion drug depending on where it's administered, you're not alone. And more importantly, you're likely overpaying. The gap between hospital infusion centers and home settings can be staggering. A single infusion might cost your plan $18,000 in a hospital, $7,000 in an outpatient infusion center, or just $3,000 at home. Same drug. Same bag. Same IV. But the price tag swings as wide as your budget allows.
The real culprit? Misaligned incentives between the vendors managing your benefit. When your Pharmacy Benefit Manager (PBM), Third-Party Administrator (TPA), broker, and providers aren't pulling in the same direction, your employees suffer and costs spiral. Getting them on the same page is the fastest path to sustainable savings on specialty drugs.
Understanding Infusible and Injectable Drugs
Infusible drugs are administered directly into the vein, usually as a slow drip, in a hospital, infusion center, infusion suite, or home setting. Injectable drugs are shots under the skin or into muscle. Both can be billed under medical benefits as J-codes (Healthcare Common Procedure Coding System procedure codes), a billing term for non-oral medications administered by a clinician.
The critical distinction? Where the drug is administered. Hospital outpatient departments, infusion centers, physician offices, and home infusion each charge differently for the exact same drug. Hospital and provider settings operate under "charge master" pricing with facility fees and provider profit spreads. That spread, called "buy and bill," is where a provider buys the drug at one cost and receives reimbursement at a much higher rate, keeping the difference.
Why Benefit Placement and J-Code Conversion Matter
Most employers have the option to steer infusible drugs toward their pharmacy benefit instead of the medical benefit. This shift, called J-code conversion, is the leverage point most employers overlook.
When drugs stay on the medical benefit, your plan loses transparency and control. Providers charge what the market will bear. Rebates don't flow through. There's no visibility into pricing spreads. When the PBM moves the drug to pharmacy, everything changes. Pricing becomes transparent. Rebates are captured and passed back to the employer. The PBM can apply cost containment programs like patient assistance programs, copay cards, and international sourcing options.
The three bagging methods determine how this works in practice. White bagging is when a specialty pharmacy sources the drug and ships it directly to the administering provider. Brown bagging is when the drug ships to the patient, who brings it to the provider, common in international sourcing. Clear bagging happens when a specialty pharmacy embedded within a health system dispenses the drug, minimizing friction.
The Alignment Problem and How to Fix It
Here's the painful truth: most J-code conversions fail because the TPA and PBM aren't aligned.
The TPA must adopt a medical exclusionary formulary, a formal list of J-code drugs it agrees not to cover under the medical benefit. This forces the claim to pharmacy. If the TPA refuses, providers simply submit claims on the medical side and pocket the buy-and-bill spread, bypassing the PBM's cost containment strategy entirely.
Why would a TPA resist? Two reasons, usually neither clinical. First, many TPAs generate significant revenue from medical claims. If drug spend moves to pharmacy, their revenue drops. Second, providers pressure TPAs hard because exclusions eliminate their profit margins.
The PBM, meanwhile, needs operational capability to procure drugs, optimize site of care, and make white bagging seamless for providers. If providers face friction or complexity, they'll resist and revert to buying and billing on their own.
Employees and employers win when drugs move to pharmacy and costs drop. But this only works if your vendors are genuinely incentivized to cooperate, not just willing to comply when you ask.
The One Change That Matters Most
If you make just one change this year, align your incentives. Ask your PBM directly: Do you have a J-code conversion program? If they don't, walk. Ask your TPA: Will you adopt a medical exclusionary formulary? If they resist, ask why. Resistance usually means either they don't want the operational work or they don't want that medical revenue walking out the door.
The most effective step? Move your pharmacy benefit to a transparent, independent PBM without vertical conflicts. When your PBM doesn't own a health plan or hospital network, they're incentivized to save you money, not keep drugs on expensive settings. They can partner with any provider without protecting their own turf.
Your vendors won't fix misalignment unless you hold them accountable. And once aligned, you'll see real differences in your claims data. The question is whether you're willing to ask the hard questions first.
Want to go deeper?
Want to learn more about containing costs on infusible drugs? Check out the Generous Benefits Podcast episode where Amanda Brummitt and Ali Goodwin break it down: https://generousbenefits.podbean.com/e/containing-costs-on-infusible-drugs-starts-with-vendor-alignment/
